{"brief_title": "Reduction in the Occurrence of Center-Involved Diabetic Macular Edema", "brief_summary": "The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.", "condition": "Diabetic Retinopathy", "intervention_type": "Drug", "intervention_name": "placebo", "description": "QD oral for up to 36 months", "arm_group_label": "Placebo", "other_name": "Arxxant", "criteria": "Inclusion Criteria: - Type 1 or Type 2 diabetes - 18 years or older - Non-clinically significant diabetic macular edema - Mild to moderate diabetic retinopathy in the study eye, vitreous hemorrhage in the study eye - Relatively good vision (20/30 or better) Exclusion Criteria: - Surgery or laser treatment in the study eye - Glaucoma in the study eye - Glycosylated hemoglobin (HbA1c) greater than 11%, or systolic blood pressure greater than 170 millimeters of mercury (mmHg) - Liver disease, dialysis or renal transplant", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00090519.xml"}